Stock listing

NASDAQ:TRDA Entrada Therapeutics, Inc. Stock

Home listing (NASDAQ) of Entrada Therapeutics, Inc.

Follow Entrada Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TRDA

$4.35 USD -0.68 (-13.5%)

Close on Nov 20, 2026

Past year -52.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.32 – $4.58 USDNov 20, 2026
Volume
347,920 sharesNov 20, 2026
Market cap
$170.3M USDAt the close on Nov 20, 2026 · price × 39.15M shares outstanding
52-week range
$4.11 – $16.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.22M USDMedian day 371,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Entrada Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TRDA · Home$4.35 USD-0.68 (-13.5%)347,920$4.55$4.58$4.32$5.03Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TRDA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.35-0.68-13.5%$4.55$4.58$4.32347,920
$5.03+0.07+1.4%$4.94$5.50$4.81815,227
$4.96-0.04-0.8%$5.04$5.435$4.91432,577
$5.00-0.09-1.8%$5.00$5.22$4.84607,027
$5.09-0.08-1.5%$5.17$5.245$4.91791,634
$5.17-0.27-5.0%$5.33$5.425$4.94808,660
$5.44+0.19+3.6%$5.25$5.49$4.961760,792
$5.25+0.56+11.9%$4.64$5.29$4.64582,088
$4.69-0.20-4.1%$4.85$4.89$4.543500,223
$4.89+0.34+7.5%$4.60$4.91$4.535486,475
$4.55-0.51-10.1%$5.05$5.068$4.52305,203
$5.06+0.34+7.2%$4.83$5.125$4.605497,633
$4.72-0.39-7.6%$5.08$5.08$4.615563,121
$5.11+0.575+12.7%$4.58$5.13$4.44651,953
$4.535+0.135+3.1%$4.37$4.545$4.26317,344
$4.40-0.44-9.1%$4.76$5.07$4.35479,051
$4.84+0.43+9.8%$4.38$4.88$4.33409,094
$4.41-0.34-7.2%$4.72$4.85$4.36413,453
$4.75+0.34+7.7%$4.46$4.945$4.46617,085
$4.41-0.32-6.8%$4.67$4.695$4.385191,500
$4.73+0.08+1.7%$4.71$4.78$4.555462,100
$4.65-0.34-6.8%$5.02$5.035$4.60323,800
$4.99+0.17+3.5%$4.81$5.27$4.79403,100
$4.82+0.45+10.3%$4.36$4.84$4.27585,600
$4.37-0.41-8.6%$4.79$4.85$4.345371,800
$4.78+0.23+5.1%$4.52$4.96$4.425514,800
$4.55-0.31-6.4%$4.69$4.77$4.109740,100
$4.86-0.64-11.6%$5.50$5.56$4.83255,200
$5.50-0.17-3.0%$5.64$5.69$5.48198,600
$5.67+0.14+2.5%$5.52$5.75$5.44209,400
$5.53-0.08-1.4%$5.52$5.59$5.25361,500
$5.61+0.19+3.5%$5.33$5.66$5.30297,400
$5.42-0.06-1.1%$5.52$5.52$5.25315,900
$5.48+0.10+1.9%$5.38$5.48$5.15463,800
$5.38-0.30-5.3%$5.77$6.22$5.17463,700
$5.68-0.67-10.6%$6.32$6.36$5.60425,100
$6.35+0.09+1.4%$6.20$6.39$6.125239,900
$6.26+0.04+0.6%$6.25$6.43$6.08268,600
$6.22+0.06+1.0%$6.13$6.24$5.925442,600
$6.16-0.06-1.0%$6.23$6.245$6.01374,000
$6.22-0.28-4.3%$6.47$6.47$6.14319,100
$6.50-0.21-3.1%$6.71$6.71$6.37282,800
$6.71+0.07+1.1%$6.71$6.93$6.654195,500
$6.64-0.11-1.6%$6.81$6.81$6.455375,300
$6.75-0.15-2.2%$6.85$6.89$6.60354,400
$6.90+0.01+0.1%$6.91$7.05$6.665297,400
$6.89+0.01+0.1%$6.92$6.99$6.74249,200
$6.88-0.17-2.4%$7.05$7.05$6.67247,800
$7.05+0.25+3.7%$6.80$7.07$6.72336,100
$6.80+0.38+5.9%$6.49$6.81$6.29291,800
$6.42-0.69-9.7%$7.00$7.175$6.38448,100
$7.11-0.41-5.5%$7.47$7.55$7.02382,000
$7.52+0.39+5.5%$7.02$7.70$6.945514,200
$7.13-0.04-0.6%$7.11$7.17$7.00341,700
$7.17-0.13-1.8%$7.31$7.423$7.04395,600
$7.30+0.23+3.3%$7.07$7.34$6.96306,500
$7.07+0.02+0.3%$6.95$7.179$6.80205,500
$7.05+0.05+0.7%$6.84$7.17$6.76450,400
$7.00-0.27-3.7%$7.18$7.24$6.935111,600
$7.27+0.27+3.9%$7.02$7.37$6.80248,600
$7.00-0.62-8.1%$7.55$7.64$6.954229,300
$7.62+0.29+4.0%$7.39$7.67$7.39269,980
$7.33-0.24-3.2%$7.58$7.58$7.12184,249
$7.57-0.03-0.4%$7.64$7.735$7.44141,000
$7.60-0.18-2.3%$7.76$7.765$7.30250,000
Ticker
NASDAQ:TRDA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Entrada Therapeutics, Inc. news

Entrada Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 75 in all · newest Nov 18, 2026 · oldest 2021
Decks
9 decks · latest August 2026

Where Entrada Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TRDA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TRDABOATSUnited StatesUSD

Valuation

EV/sales 6.2× against a median of 16.4×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$24.60M USD
P/E
Loss
EV/sales
6.2×
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
57.5%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.2×
Beta vs S&P 500
1.43

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Entrada Therapeutics, Inc. · NASDAQ:TRDAUS$170.3MUS$24.60Mn/a6.2×n/a0.9×n/a0.2×1.43
Korro Bio, Inc. · NASDAQ:KRROUS$179.4MUS$74.36Mn/a57.6×n/a2.0×n/a0.0×1.46
Vogenx Inc · NASDAQ:VOGXUS$176.3MUS$94.21Mn/an/an/a2.1×n/a0.0×n/a
MediWound Ltd. · NASDAQ:MDWDUS$175.5MUS$155.9Mn/a15.6×n/a5.5×−235.0%0.3×0.64
Nanexa AB · OMXSTO:NANEXAUS$175.1MUS$170.1Mn/a51.4×n/a13.5×−72.5%0.0×n/a
Compugen Ltd. · NASDAQ:CGENUS$174.3MUS$59.55M4.8×0.8×n/a2.1×47.9%0.0×1.49
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H · HKEX:2591US$170.8MUS$40.22Mn/a2.1×n/a1.2×−259.6%0.2×n/a
SinoMab Bioscience Ltd. · HKEX:3681US$166.3MUS$172.4Mn/an/an/a3.1×n/a0.7×n/a
Prestige BioPharma Limited · KRX:950210US$165.8MUS$132.7Mn/a6.8×n/a0.5×−350.9%0.1×n/a
Acepodia, Inc. · TPEX:6976US$162.7MUS$58.46Mn/a10,415×n/a1.1×n/a0.0×n/a
TaiGen Biopharmaceuticals Holdings Limited · TPEX:4157US$161.1MUS$133.4M34.2×17.1×46.8×5.2×60.5%0.0×n/a
Median of the othersUS$172.5MUS$113.5M19.5×16.4×46.8×2.1×−153.8%0.0×1.46

Forecasts

6 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
17.75 USD · Analysts' mean
EPS, year to Dec 2026
-3.90 · 5 analysts
Revenue, year to Dec 2026
5.49M · 6 analysts

Team and board

Officers

OfficerRole
Dipal DoshiChief Executive Officer
Kory WentworthChief Financial Officer
Natarajan SethuramanPresident of Research and Development
Nathan J. DowdenPresident and Chief Operating Officer
Jared CohenGeneral Counsel
Doug SnowHead of Investor Relations
Kevin HealySenior Vice President, Regulatory Affairs
Karla MacDonaldChief Corporate Affairs Officer
Linea AspesiChief People Officer

Board

DirectorRole
Kush M. ParmarManaging Partner, 5am Ventures (Board Chairman)
Bernhardt ZeiherIndustry Leader and Independent Director
Dipal DoshiChief Executive Officer
Gina ChapmanIndustry Leader and Independent Director
Maha RadhakrishnanIndustry Leader and Independent Director
Mary ThistleIndustry Leader and Independent Director
Peter S. KimVirginia and D.K. Ludwig Professor of Biochemistry, Stanford University

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−10.1%
Q2 2026Aug 5, 2026 · Before open−2.5%
Q1 2026May 7, 2026 · Before open−57.3%
Q4 2025Feb 26, 2026−0.4%
Q3 2025Nov 6, 2025 · Before open+0.1%
Q2 2025Aug 6, 2025 · Before open+2.1%
Q1 2025May 8, 2025 · Before open+5.6%
Q4 2024Mar 3, 2025−8.0%
Q3 2024Nov 5, 2024 · Before open+4.8%
Q2 2024Aug 13, 2024 · Before open+11.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open+2.8%
Q4 2023Mar 13, 2024 · Before open+9.8%
Q3 2023Nov 7, 2023 · Before open+8.6%
Q2 2023Aug 8, 2023 · Before open+10.5%
Q1 2023May 10, 2023 · Before open−2.1%
Q4 2022Mar 6, 2023 · Before open−1.4%
Q3 2022Nov 7, 2022 · Before open−10.0%
Q2 2022Aug 11, 2022 · Before open+0.7%
Q1 2022May 12, 2022 · Before open+10.3%
Q4 2021Mar 15, 2022 · Before open+9.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck50 slidesAugust 2026
Investor Presentation (May 2026)Investor deck51 slidesMay 19, 2026
2025 J.P. Morgan Healthcare ConferenceConference25 slidesJan 15, 2025
Targeted Intracellular Delivery Summit 2023Conference24 slidesMar 8, 2023
PPMD 2023 Annual ConferenceConference9 slides2023
CureDuchenne FUTURES 2023Conference11 slides2023
Boulder Peptide Symposium 2022Conference29 slidesNov 10, 2022
CureDuchenne Futures 2022Conference10 slides2022
MDF 2022Conference12 slides2022

Open Decks

IPO

Priced at US$20.00 a share on Oct 28, 2021.

Price
US$20.00 a share
Shares offered
9,075,000 shares of common stock
Offering size
US$181.5 million
Underwriters' option
Up to 1,361,250 more shares
Listing
TRDA on the Nasdaq Global Market
Underwriters
Goldman Sachs & Co. LLC, Cowen, Evercore ISI · In the order on the cover
Shares delivered
On or about Nov 2, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceAug 6, 2021
Filed publiclyOct 8, 2021
Amended onceOct 25, 2021
Shares registered with an exchangeOct 26, 2021
Declared effective by the SECOct 28, 2021
Final prospectus, with the priceNov 1, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Nov 1, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue25.4M210.8M129.0M25.3M000
Cost of revenue4.10M3.77M99.9M1.90M1.12M326.0K104.0K
Gross profit21.3M210.8M129.0M-1.90M-1.12M-326.0K-104.0K
Research and development142.3M125.3M99.9M66.6M35.9M21.1M8.22M
Selling, general and administrative41.0M38.5M32.3M30.6M15.2M5.57M3.61M
Operating income-157.9M47.0M-3.16M-97.2M-51.1M-26.7M-11.8M
Depreciation and amortization4.10M3.77M2.84M1.90M1.12M326.0K104.0K
EBITDA-153.8M50.8M-321.0K-95.4M-50.0M-26.3M-11.7M
Interest expense2.63M31.0K00
Income before tax-142.8M66.5M12.1M-94.6M-51.2M-26.5M-5.10M
Income tax924.0K859.0K18.7M000-451.0K
Net income-143.8M65.6M-6.68M-94.6M-51.2M-26.5M-4.65M
Earnings per share, basic-3.471.76-0.20-3.02-8.16-24.00-4.44
Earnings per share, diluted-3.471.68-0.20-3.02-8.16-24.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents90.4M101.2M67.6M45.2M291.1M39.0M16.8M
Short-term investments205.3M318.8M284.4M143.6M0
Receivables2.58M3.68M5.88M872.0K
Inventory1
Current assets306.3M440.0M369.8M209.9M298.7M39.9M17.4M
Property, plant and equipment7.31M10.9M11.2M7.68M6.26M3.04M801.0K
Total assets377.4M526.3M469.2M252.1M305.8M43.5M18.2M
Accounts payable2.29M4.26M3.28M5.99M706.0K1.60M710.0K
Current liabilities24.5M39.5M158.8M22.0M6.72M3.36M1.92M
Total debt50.9M59.2M68.2M25.9M
Total liabilities71.2M97.6M226.8M39.5M7.12M3.36M33.8M
Shareholders' equity306.1M428.7M242.4M212.6M298.7M-41.5M-15.5M
Shares outstanding38.3M37.6M33.4M31.4M31.2M1.24M1.05M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-128.5M-41.6M139.8M-93.8M-50.9M-25.6M-10.8M
Capital spending-1.04M-3.16M-5.61M-2.89M-4.58M-2.32M-630.0K
Free cash flow-129.6M-44.7M134.2M-96.7M-55.4M-27.9M-11.4M
Cash from investing116.8M-27.8M-138.4M-148.7M-4.58M-2.32M-630.0K
Cash from financing887.0K103.0M21.0M479.0K307.5M50.1M38.0K
Share buybacks462.0K574.0K443.0K284.0K191.1M
Change in cash-10.8M33.6M22.4M-242.0M252.0M22.2M16.8M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportOct 14, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 10, 2026Big-stake noticeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedAug 10, 2026Other filingsSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
144 · Notice of proposed saleJul 30, 2026Other filingsSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Management or board changeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
8-K · Current reportMay 18, 2026Current reportSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 4, 2026Other filingsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
8-K · Current reportJan 8, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveDec 4, 2025Other filingsSEC
CORRESP · Letter to the SECDec 1, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 25, 2025Big-stake noticeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 18, 2025Big-stake noticeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
144 · Notice of proposed saleNov 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
S-3 · Registration statementNov 6, 2025Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
4 · Change in ownershipJul 11, 2025Insider tradeSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJul 1, 2025Other filingsSEC
144 · Notice of proposed saleJun 30, 2025Other filingsSEC
144 · Notice of proposed saleJun 30, 2025Other filingsSEC
144 · Notice of proposed saleJun 27, 2025Other filingsSEC
144 · Notice of proposed saleJun 27, 2025Other filingsSEC
4/A · Change in ownership, amendedJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Meeting outcomeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 3, 2025Insider tradeSEC
DEFA14A · Additional proxy materialJun 3, 2025Meeting noticeSEC
8-K · Current reportJun 3, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
8-K · Current reportApr 29, 2025Current reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 25, 2025Offer documentSEC
8-K · Current reportMar 24, 2025Current reportSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
8-K · Current reportFeb 24, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
8-K · Current reportFeb 3, 2025Current reportSEC
8-K · Current reportJan 15, 2025ResultsSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024ResultsSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
144 · Notice of proposed saleSep 9, 2024Other filingsSEC
144 · Notice of proposed saleSep 6, 2024Other filingsSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
144 · Notice of proposed saleAug 16, 2024Other filingsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
4 · Change in ownershipJul 16, 2024Insider tradeSEC
144 · Notice of proposed saleJul 15, 2024Other filingsSEC
144 · Notice of proposed saleJul 12, 2024Other filingsSEC
4 · Change in ownershipJul 10, 2024Insider tradeSEC
144 · Notice of proposed saleJul 8, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedJun 26, 2024Big-stake noticeSEC
4 · Change in ownershipJun 26, 2024Insider tradeSEC
8-K · Current reportJun 24, 2024Material contractSEC
424B5 · ProspectusJun 24, 2024Offer documentSEC
8-K · Current reportJun 24, 2024Current reportSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
144 · Notice of proposed saleJun 13, 2024Other filingsSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 16, 2024Insider tradeSEC
144 · Notice of proposed saleMay 16, 2024Other filingsSEC
144 · Notice of proposed saleMay 16, 2024Other filingsSEC
4 · Change in ownershipMay 10, 2024Insider tradeSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
144 · Notice of proposed saleApr 30, 2024Other filingsSEC
144 · Notice of proposed saleApr 29, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
144 · Notice of proposed saleApr 26, 2024Other filingsSEC
144 · Notice of proposed saleApr 25, 2024Other filingsSEC
144 · Notice of proposed saleApr 24, 2024Other filingsSEC
144 · Notice of proposed saleApr 23, 2024Other filingsSEC
144 · Notice of proposed saleApr 19, 2024Other filingsSEC
PRE 14A · Preliminary proxy statementApr 19, 2024Meeting noticeSEC
144 · Notice of proposed saleApr 18, 2024Other filingsSEC
144 · Notice of proposed saleApr 17, 2024Other filingsSEC

This page holds 200 of 474 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Entrada Therapeutics, Inc.’s releases · as of Oct 31, 2026

Common shares
39,150,334
Fully diluted
39,150,334

Fully diluted

LineSharesAs of
Common shares39,150,334Oct 31, 2026

Share count over time

CountShares
Oct 31, 202639,150,334

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Baker Bros. Advisors LP5.07M13.0%US$32.2MSep 30, 2026
5AM Venture Management, LLC3.78M9.7%US$24MSep 30, 2026
BlackRock3.24M8.3%US$20.6MSep 30, 2026
Merck & Co., Inc.1.74M4.4%US$11MSep 30, 2026
Vanguard1.72M4.4%US$10.9MSep 30, 2026
Trails Edge Capital Partners, LP1.43M3.6%US$9.07MSep 30, 2026
TCG Crossover Management, LLC1.06M2.7%US$6.73MSep 30, 2026
Wellington954K2.4%US$6.06MSep 30, 2026
StepStone Group LP761K1.9%US$4.83MSep 30, 2026
Geode Capital708K1.8%US$4.5MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Acadian Asset Management LLC649K1.7%US$4.12MSep 30, 2026
UBS628K1.6%US$3.99MSep 30, 2026
AQR Capital Management LLC624K1.6%US$3.96MSep 30, 2026
State Street589K1.5%US$3.74MSep 30, 2026
JPMorgan507K1.3%US$3.17MSep 30, 2026
Citadel462K1.2%US$2.93MSep 30, 2026
Morgan Stanley386K0.99%US$2.45MSep 30, 2026
Millennium345K0.88%US$2.19MSep 30, 2026
Dimensional344K0.88%US$2.18MSep 30, 2026
Northern Trust299K0.76%US$1.9MSep 30, 2026
Goldman Sachs298K0.76%US$1.89MSep 30, 2026
Lynx1 Capital Management LP279K0.71%US$1.77MSep 30, 2026
J. Goldman & Co LP268K0.68%US$1.7MSep 30, 2026
Gsa Capital Partners LLP263K0.67%US$1.67MSep 30, 2026
Schwab252K0.64%US$1.6MSep 30, 2026
BNP Paribas233K0.59%US$1.48MSep 30, 2026
Longaeva Partners L.P.227K0.58%US$1.44MSep 30, 2026
Renaissance Technologies199K0.51%US$1.26MSep 30, 2026
Jacobs Levy Equity Management, Inc185K0.47%US$1.17MSep 30, 2026
Quantinno Capital Management LP166K0.42%US$1.05MSep 30, 2026
D. E. Shaw & Co., Inc.157K0.40%US$998KSep 30, 2026
Bank of America150K0.38%US$956KSep 30, 2026
Qube Research & Technologies Ltd150K0.38%US$954KSep 30, 2026
Woodline Partners LP146K0.37%US$925KSep 30, 2026
Trexquant Investment LP140K0.36%US$888KSep 30, 2026
T. Rowe Price124K0.32%US$791KSep 30, 2026
HSBC120K0.31%US$758KSep 30, 2026
Allspring Global Investments Holdings, LLC117K0.30%US$740KSep 30, 2026
Two Sigma111K0.28%US$708KSep 30, 2026
Moore Capital Management, LP105K0.27%US$667KSep 30, 2026
Voleon Capital Management LP105K0.27%US$666KSep 30, 2026
Point72 Asset Management, L.P.102K0.26%US$646KSep 30, 2026
Diadema Partners LP100K0.26%US$635KSep 30, 2026
Jump Financial, LLC82,2590.21%US$522KSep 30, 2026
American Century79,5470.20%US$505KSep 30, 2026
BNY78,9910.20%US$502KSep 30, 2026
XTX Topco Ltd75,0160.19%US$476KSep 30, 2026
Barclays70,6250.18%US$448KSep 30, 2026
Susquehanna64,9130.17%US$412KSep 30, 2026
Nuveen60,7220.16%US$386KSep 30, 2026

This page holds 50 of 128 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund954K2.4%US$7.02MJun 30, 2026
iShares Russell 2000 ETF768K2.0%US$5.65MJun 30, 2026
Fidelity Small Cap Index Fund322K0.82%US$2.19MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.296K0.76%US$2.18MJun 30, 2026
Vanguard Extended Market Index Fund283K0.72%US$2.08MJun 30, 2026
iShares Russell 2000 Value ETF271K0.69%US$1.99MJun 30, 2026
JPMorgan U.S. Small Company Fund175K0.45%US$1.29MJun 30, 2026
iShares Biotechnology ETF151K0.39%US$1.11MJun 30, 2026
Vanguard Russell 2000 Index Fund146K0.37%US$1.03MMay 31, 2026
Fidelity Extended Market Index Fund127K0.32%US$899KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Schwab U.S. Small-Cap ETF113K0.29%US$802KMay 31, 2026
Dimensional U.S. Small Cap ETF108K0.28%US$737KJul 31, 2026
iShares Micro-Cap ETF98,8520.25%US$728KJun 30, 2026
Schwab Small-Cap Index Fund71,9470.18%US$489KJul 31, 2026
Multi-Manager Small Cap Equity Strategies Fund70,2800.18%US$497KMay 31, 2026
Avantis U.S. Small Cap Equity ETF69,4120.18%US$491KMay 31, 2026
Allspring Disciplined Small Cap Fund62,6250.16%US$461KJun 30, 2026
U.S. Micro Cap Portfolio62,3890.16%US$424KJul 31, 2026
Master Small Cap Index Series58,3980.15%US$430KJun 30, 2026
Vanguard Health Care Index Fund57,1150.15%US$404KMay 31, 2026
Royce Capital Fund - Small-Cap Portfolio51,4700.13%US$379KJun 30, 2026
NVIT Multi-Manager Small Company Fund46,7520.12%US$344KJun 30, 2026
Small Cap Value Fund45,7270.12%US$337KJun 30, 2026
NVIT Small Cap Value Fund43,5660.11%US$321KJun 30, 2026
Fidelity Total Market Index Fund41,1880.11%US$291KMay 31, 2026
Fidelity Small Cap Value Index Fund40,9970.10%US$302KJun 30, 2026
LVIP JPMorgan Small Cap Core Fund37,9590.10%US$279KJun 30, 2026
Fidelity Series Total Market Index Fund37,2370.10%US$263KMay 31, 2026
Nuveen Small Cap Blend Index Fund33,4810.09%US$227KJul 31, 2026
Harbor Human Capital Factor US Small Cap ETF33,3690.09%US$227KJul 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF33,0550.08%US$234KMay 31, 2026
Small Cap Equity Fund31,7650.08%US$234KJun 30, 2026
Royce Small-Cap Value Fund31,4320.08%US$231KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund30,2950.08%US$223KJun 30, 2026
U.S. Small Cap Value Portfolio29,9840.08%US$204KJul 31, 2026
U.S. Small Cap Portfolio28,9800.07%US$197KJul 31, 2026
EQ/2000 Managed Volatility Portfolio28,9070.07%US$213KJun 30, 2026
Fidelity Nasdaq Composite Index Fund28,2110.07%US$199KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF27,0630.07%US$184KJul 31, 2026
Vy(R) Jpmorgan Small Cap Core Equity Portfolio25,0280.06%US$184KJun 30, 2026
Ultra-Small Company Market Fund25,0000.06%US$184KJun 30, 2026
Vanguard Russell 2000 Value Index Fund22,6730.06%US$160KMay 31, 2026
Nuveen Equity Index Fund21,3200.05%US$145KJul 31, 2026
T. Rowe Price Health Sciences Portfolio20,1590.05%US$148KJun 30, 2026
LVIP State Street Small-Cap Index Fund18,3000.05%US$135KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund17,8420.05%US$131KJun 30, 2026
Schwab U.S. Broad Market ETF17,2610.04%US$122KMay 31, 2026
U.S. Vector Equity Portfolio16,1290.04%US$110KJul 31, 2026
EQ/Small Company Index Portfolio15,8800.04%US$117KJun 30, 2026
Small Cap Index Fund15,3360.04%US$113KJun 30, 2026

This page holds 50 of 137 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Mpm Bioventures 2018 (B), L.P.
10% owner
Sale28,837USD 7.13US$206KSep 9, 2026
MPM BioVentures 2018 GP LLC
10% owner
Sale28,837USD 7.13US$206KSep 9, 2026
Mpm Bioventures 2018 (B), L.P.
10% owner
Sale192,500USD 7.41US$1.43MSep 8, 2026
MPM BioVentures 2018 GP LLC
10% owner
Sale192,500USD 7.41US$1.43MSep 8, 2026
Mpm Bioventures 2018 (B), L.P.
10% owner
Sale38,500USD 7.11US$274KSep 4, 2026
MPM BioVentures 2018 GP LLC
10% owner
Sale38,500USD 7.11US$274KSep 4, 2026
MPM BioVentures 2014 GP LLC
10% owner
Sale32,263USD 7.17US$231KSep 3, 2026
MPM BioVentures 2018 LLC
10% owner
Sale32,263USD 7.17US$231KSep 3, 2026
MPM BioVentures 2014 GP LLC
10% owner
Sale25,131USD 7.19US$181KSep 2, 2026
MPM BioVentures 2018 LLC
10% owner
Sale25,131USD 7.19US$181KSep 2, 2026
All 37 trades
TradeTradeSharesPriceValueDate
MPM BioVentures 2014 GP LLC
10% owner
Sale29,088USD 7.06US$205KSep 1, 2026
MPM BioVentures 2018 LLC
10% owner
Sale29,088USD 7.06US$205KSep 1, 2026
MPM BioVentures 2014 (B), L.P.
10% owner
Sale44,259USD 6.99US$309KAug 31, 2026
MPM BioVentures 2018 LLC
10% owner
Sale44,259USD 6.99US$309KAug 31, 2026
MPM BioVentures 2014 (B), L.P.
10% owner
Sale3,733USD 7.01US$26,168Aug 28, 2026
MPM BioVentures 2018 LLC
10% owner
Sale3,733USD 7.01US$26,168Aug 28, 2026
MPM BioVentures 2014 (B), L.P.
10% owner
Sale38,922USD 7.20US$280KAug 27, 2026
MPM BioVentures 2018 LLC
10% owner
Sale38,922USD 7.20US$280KAug 27, 2026
MPM BioVentures 2018 LLC
10% owner
Sale14,569USD 7.06US$103KAug 26, 2026
Todd Foley
10% owner
Sale14,569USD 7.06US$103KAug 26, 2026
MPM BioVentures 2018 LLC
10% owner
Sale26,522USD 7.54US$200KAug 25, 2026
Todd Foley
10% owner
Sale26,522USD 7.54US$200KAug 25, 2026
MPM BioVentures 2018 LLC
10% owner
Sale21,623USD 7.34US$159KAug 24, 2026
Todd Foley
10% owner
Sale21,623USD 7.34US$159KAug 24, 2026
Parmar Kush
Director
Sale92,444USD 7.00US$647KAug 10, 2026
Rocklage Scott M
10% owner
Sale52,317USD 6.85US$358KAug 7, 2026
Parmar Kush
Director
Sale52,317USD 6.85US$358KAug 7, 2026
Rocklage Scott M
10% owner
Sale10,494USD 7.00US$73,458Aug 6, 2026
Parmar Kush
Director
Sale10,494USD 7.00US$73,458Aug 6, 2026
Rocklage Scott M
10% owner
Sale1,718USD 6.85US$11,768Jul 31, 2026
Parmar Kush
Director, 10% owner
Sale1,718USD 6.85US$11,768Jul 31, 2026
Rocklage Scott M
10% owner
Sale114,756USD 6.93US$795KJul 30, 2026
Parmar Kush
Director, 10% owner
Sale114,756USD 6.93US$795KJul 30, 2026
Zeiher Bernhardt G
Director
Buy5,000USD 5.86US$29,300May 20, 2026
Dowden Nathan J
Officer: President & COO
Sale15,000USD 15.33US$230KMay 4, 2026
Sethuraman Natarajan
Officer: President, Research & Develop.
Sale25,907USD 15.39US$399KMay 4, 2026
Wentworth Kory James
Officer: Chief Financial Officer
Sale2,500USD 12.95US$32,375Apr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Kush Parmar10.80%4.12MNov 14, 2025Schedule 13D
ANSBERT GADICKE9.90%3.89MSep 8, 2026Schedule 13D
Roche Finance Ltd6.90%2.57MDec 31, 2024Schedule 13G
BlackRock, Inc.5.30%1.97MDec 31, 2024Schedule 13G
Janus Henderson Group PLC4.00%1.52MJun 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mary Thistle
Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Cullinan Therapeutics, Inc. (Chair of the Compensation Committee · Since at least Aug 8, 2024); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Q32 Bio Inc. (Director · Since at least Mar 27, 2018); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past)
Industry Leader and Independent Director · Since at least Oct 28, 2021
John F Crowley
Other companies: Intellia Therapeutics, Inc. (Director · Oct 2, 2020 – Jun 14, 2023 · Past); Amicus Therapeutics Inc (Executive Chairman, Director · Dec 31, 2011 – Mar 1, 2024 · Past)
Director · Oct 28, 2021 – Jun 8, 2023 · Past
Maha Radhakrishnan
Other companies: Candel Therapeutics, Inc. (Director · Since at least Jun 4, 2025); Alto Neuroscience, Inc. (Director · Mar 8, 2024 – Mar 8, 2024 · Past)
Industry Leader and Independent Director · Since at least Jun 1, 2025
Nerissa Kreher
Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Jun 30, 2026); Rezolute, Inc. (Board Member · Since at least Jun 23, 2022)
Chief Medical Officer · Jul 1, 2022 – Sep 1, 2023 · Past
Dipal Doshi
Other companies: Azenta, Inc. (Director · Since at least Jan 30, 2025)
Chief Executive Officer · Since at least Jun 27, 2022
Gina Chapman
Other companies: CARGO Therapeutics, Inc. (President & CEO, Director · Nov 9, 2023 – Mar 14, 2025 · Past)
Industry Leader and Independent Director · Since at least Sep 1, 2023
Kory Wentworth
Other companies: Bluebird bio Inc (Principal Accounting Officer · Dec 18, 2017 – Aug 3, 2020 · Past)
Chief Financial Officer · Since at least Oct 28, 2021
Bernhardt ZeiherIndustry Leader and Independent Director · Since at least May 21, 2026
Caileigh DoughertyHead of Investor Relations & Corporate Communications · Mar 24, 2025 – Nov 4, 2026 · Past
ContactCaileigh DoughertyHeadof Investor Relations & Corporate · Feb 3, 2025 – Nov 4, 2026 · Past
All 19 people
PersonSeat
Doug SnowHead of Investor Relations · Since at least Oct 21, 2026
Jared CohenGeneral Counsel · Since at least Nov 5, 2026
Karla MacDonaldChief Corporate Affairs Officer · Since at least May 6, 2026
Kevin HealySenior Vice President, Regulatory Affairs · Since at least Nov 5, 2026
Kush M. ParmarManaging Partner, 5am Ventures (Board Chairman) · Since at least Jun 11, 2025
Linea AspesiChief People Officer · Since at least Oct 21, 2026
Natarajan SethuramanPresident of Research and Development · Since at least Oct 28, 2021
Nathan J. DowdenPresident and Chief Operating Officer · Since at least Sep 3, 2026
Peter S. KimVirginia and D.K. Ludwig Professor of Biochemistry, Stanford University · Since at least Oct 28, 2021

Open People

Log in to ask 6ix AI your own questions about Entrada Therapeutics, Inc.